Markus Jensen

Summary

Affiliation: University of Cologne
Country: Germany

Publications

  1. pmc The bi-specific CD3 x NCAM antibody: a model to preactivate T cells prior to tumour cell lysis
    M Jensen
    Department of Pediatric Oncology and Hematology, University of Cologne, Germany
    Clin Exp Immunol 134:253-63. 2003
  2. ncbi request reprint Targeting the neural cell adhesion molecule in cancer
    Markus Jensen
    Department of Paediatric Oncology and Haematology, University of Cologne, Kerpener Strasse 62, 50924, Cologne, Germany
    Cancer Lett 258:9-21. 2007
  3. ncbi request reprint NK cell depletion diminish tumour-specific B cell responses
    Markus Jensen
    Molecular Tumour Biology and Tumour Immunology, University of Cologne, Cologne, Germany
    Immunol Lett 93:205-10. 2004
  4. ncbi request reprint Phase I study of a novel pro-apoptotic drug R-etodolac in patients with B-cell chronic lymphocytic leukemia
    Markus Jensen
    University of Cologne, Kerpener Strasse 62, 50924, Cologne, Germany
    Invest New Drugs 26:139-49. 2008
  5. ncbi request reprint One step generation of fully chimeric antibodies using Cgamma1- and Ckappa mutant mice
    Markus Jensen
    Department of Pediatric Oncology, University of Cologne, Cologne, Germany
    J Immunother 30:338-49. 2007
  6. ncbi request reprint Prolonged remission in a patient with relapsed follicular lymphoma after a single course of rituximab
    Markus Jensen
    Department of Internal Medicine I, University of Cologne, Germany
    Onkologie 29:90-2. 2006
  7. doi request reprint The novel chimeric anti-NCAM (neural cell adhesion molecule) antibody ch.MK1 displays antitumor activity in SCID mice but does not activate complement-dependent cytolysis (CDC)
    Martin Klehr
    Department of Pediatric Oncology and Hematology, University of Cologne, Cologne, Germany
    J Immunother 32:442-51. 2009
  8. ncbi request reprint Localization of 131I-labelled monoclonal antibody ERIC1 in a subcutaneous xenograft model of neuroblastoma in SCID mice
    Christina Otto
    Department of Nuclear Medicine, University of Cologne, Germany
    Nucl Med Commun 27:171-8. 2006
  9. ncbi request reprint Fludarabine in combination with alemtuzumab is effective and feasible in patients with relapsed or refractory B-cell chronic lymphocytic leukemia: results of a phase II trial
    Thomas Elter
    Department of Hematology and Oncology, University of Cologne, Cologne, Germany
    J Clin Oncol 23:7024-31. 2005
  10. ncbi request reprint Reduced frequencies and suppressive function of CD4+CD25hi regulatory T cells in patients with chronic lymphocytic leukemia after therapy with fludarabine
    Marc Beyer
    Molecular Tumor Biology and Tumor Immunology Clinic I for Internal Medicine, University of Cologne, Joseph Stelzmann Str 9 Haus 16, 50931 Cologne, Germany
    Blood 106:2018-25. 2005

Collaborators

Detail Information

Publications11

  1. pmc The bi-specific CD3 x NCAM antibody: a model to preactivate T cells prior to tumour cell lysis
    M Jensen
    Department of Pediatric Oncology and Hematology, University of Cologne, Germany
    Clin Exp Immunol 134:253-63. 2003
    ....
  2. ncbi request reprint Targeting the neural cell adhesion molecule in cancer
    Markus Jensen
    Department of Paediatric Oncology and Haematology, University of Cologne, Kerpener Strasse 62, 50924, Cologne, Germany
    Cancer Lett 258:9-21. 2007
    ..Here we provide an overview of the evolving field of anti-NCAM immunotherapy for cancer and discuss its indications and limitations...
  3. ncbi request reprint NK cell depletion diminish tumour-specific B cell responses
    Markus Jensen
    Molecular Tumour Biology and Tumour Immunology, University of Cologne, Cologne, Germany
    Immunol Lett 93:205-10. 2004
    ..The data reveal an unexpected impact of NK cells on the development of tumour directed B cell responses. Consequently, NK cell function has also to be taken into account when developing B cell-based cancer immunotherapy...
  4. ncbi request reprint Phase I study of a novel pro-apoptotic drug R-etodolac in patients with B-cell chronic lymphocytic leukemia
    Markus Jensen
    University of Cologne, Kerpener Strasse 62, 50924, Cologne, Germany
    Invest New Drugs 26:139-49. 2008
    ..Further study of R-etodolac as a possible new maintenance therapy or as a part of combination therapy of B-CLL appears warranted...
  5. ncbi request reprint One step generation of fully chimeric antibodies using Cgamma1- and Ckappa mutant mice
    Markus Jensen
    Department of Pediatric Oncology, University of Cologne, Cologne, Germany
    J Immunother 30:338-49. 2007
    ..The present data highlight F004-Jen mice as an efficient tool for "one step" generation of chimeric Abs...
  6. ncbi request reprint Prolonged remission in a patient with relapsed follicular lymphoma after a single course of rituximab
    Markus Jensen
    Department of Internal Medicine I, University of Cologne, Germany
    Onkologie 29:90-2. 2006
    ..Rituximab monotherapy can achieve remissions of up to 80% in follicular lymphoma. As the antibody has only been on the market since 1997, long-term observations are still rare...
  7. doi request reprint The novel chimeric anti-NCAM (neural cell adhesion molecule) antibody ch.MK1 displays antitumor activity in SCID mice but does not activate complement-dependent cytolysis (CDC)
    Martin Klehr
    Department of Pediatric Oncology and Hematology, University of Cologne, Cologne, Germany
    J Immunother 32:442-51. 2009
    ....
  8. ncbi request reprint Localization of 131I-labelled monoclonal antibody ERIC1 in a subcutaneous xenograft model of neuroblastoma in SCID mice
    Christina Otto
    Department of Nuclear Medicine, University of Cologne, Germany
    Nucl Med Commun 27:171-8. 2006
    ..To evaluate a novel strategy of immunolocalization of human neuroblastoma by targeting the neural cell adhesion molecule (NCAM), which is over-expressed on neuroblastoma...
  9. ncbi request reprint Fludarabine in combination with alemtuzumab is effective and feasible in patients with relapsed or refractory B-cell chronic lymphocytic leukemia: results of a phase II trial
    Thomas Elter
    Department of Hematology and Oncology, University of Cologne, Cologne, Germany
    J Clin Oncol 23:7024-31. 2005
    ..To determine the efficacy and safety of a newly developed concomitant administration of fludarabine and alemtuzumab (FluCam) in patients with relapsed or refractory B-cell chronic lymphocytic leukemia (B-CLL)...
  10. ncbi request reprint Reduced frequencies and suppressive function of CD4+CD25hi regulatory T cells in patients with chronic lymphocytic leukemia after therapy with fludarabine
    Marc Beyer
    Molecular Tumor Biology and Tumor Immunology Clinic I for Internal Medicine, University of Cologne, Joseph Stelzmann Str 9 Haus 16, 50931 Cologne, Germany
    Blood 106:2018-25. 2005
    ..In light of similar findings for cyclophosphamide the combination of fludarabine and cyclophosphamide might be further exploited in strategies reducing immunosuppression prior to cancer immunotherapy...
  11. ncbi request reprint Implementation and evaluation of a central coordination office for clinical trials in a tertiary care hospital
    Sven Trelle
    Department I of Internal Medicine, University Hospital Cologne, Germany
    Onkologie 28:407-11. 2005
    ..We report about a project now running for 7 years that was started in order to enhance the recruitment of patients into clinical trials, to improve trial-related quality, and to comply with the regulatory issues related to these studies...